| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PULM | Exit | Pulmatrix, Inc. | $0 | – | -359,441 | -100.0% | -2.04% | – |
| GNCA | Exit | Genocea Biosciences, Inc. | $0 | – | -197,345 | -100.0% | -2.69% | – |
| DARE | Exit | Dare Bioscience, Inc. | $0 | – | -326,240 | -100.0% | -3.87% | – |
| LIFE | Exit | Atyr Pharma Inc. | $0 | – | -130,572 | -100.0% | -8.42% | – |
| XFOR | Exit | x4 Pharmaceuticals Inc. | $0 | – | -311,492 | -100.0% | -11.70% | – |
| LYRA | Exit | Lyra Therapeutics, Inc. | $0 | – | -1,100,852 | -100.0% | -71.28% | – |
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Fate Therapeutics, Inc. | 30 | Q2 2021 | 79.2% |
| Atyr Pharma Inc. | 26 | Q3 2021 | 15.1% |
| Trevena, Inc. | 22 | Q2 2019 | 24.9% |
| Genocea Biosciences, Inc. | 21 | Q1 2019 | 32.5% |
| Selecta Biosciences, Inc. | 20 | Q1 2021 | 39.5% |
| T2 Biosystems, Inc. | 20 | Q2 2019 | 36.1% |
| Dare Bioscience, Inc. | 17 | Q3 2021 | 3.9% |
| Pulmatrix, Inc. | 16 | Q1 2019 | 15.4% |
| Cerulean Pharma Inc | 13 | Q2 2017 | 16.2% |
| Kala Pharmaceuticals, Inc. | 11 | Q1 2020 | 37.1% |
View Polaris Venture Management Co. V, L.L.C.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 3 | 2022-03-30 |
| 13F-HR | 2021-11-12 |
| 13F-HR | 2021-08-12 |
| 13F-HR | 2021-05-12 |
| 13F-HR | 2021-02-12 |
| 13F-HR | 2020-11-12 |
| 13F-HR | 2020-08-12 |
| 13F-HR | 2020-05-14 |
| 4 | 2020-05-06 |
| 3 | 2020-04-30 |
View Polaris Venture Management Co. V, L.L.C.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.